GlaxoSmithKline (GSK) has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA dry powder ...
Tags: Asthma Treatment, Medicine
GlaxoSmithKline (GSK) and Danish biotechnology firm Genmab have filed a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of its leukaemia drug Arzerra (ofatumumab) in combination ...
Tags: GlaxoSmithKline, CLL Patients
Danish biotechnology firm Genmab has unveiled positive results from a Phase II study of its sclerosis drug candidate ofatumumab in relapsing-remitting multiple sclerosis (RRMS). In a randomized study of 232 patients with RRMS, treatment ...
Tags: Genmab, Sclerosis Drug
The US Food and Drug Administration (FDA) has approved breakthrough therapy designation for Danish biotechnology company Genmab and British pharmaceutical company GlaxoSmithKline’s (GSK) Arzerra (ofatumumab) in combination with ...
Tags: therapy designation, Medicine
Genmab and ADC Therapeutics have partnered to co-develop a new antibody-drug conjugate (ADC) product conjugate to treat multiple cancer indications. The collaboration will integrate Genmab's high-affinity fully human antibody targeting ...
Tags: Genmab, ADC Partner
Biotechnology company Genmab has obtained FDA fast track designation in double refractory multiple myeloma for daratumumab. As per the designation, the human CD38 monoclonal antibody Daratumumab is suitable for multiple myeloma patients ...
Genmab has achieved a third pre-clinical milestone that generates a payment worth €1m as part of a collaboration with Lundbeck. The deal allows Genmab, which received €7.5m upfront payment previously, to develop human ...
Tags: Genmab, clinical trial, cooperation
Janssen Biotech, a Johnson & Johnson company, has executed a license and development agreement for an investigational anti-cancer agent, daratumumab (HuMax-CD38), with Genmab. Daratumumab is a human CD38 monoclonal antibody which is ...
Tags: Daratumumab License, license and development agreement, anti-cancer
Genmab and GlaxoSmithKline (GSK) have announced the submission of a new drug application (NDA) for Arzerra (ofatumumab) to the Japanese Ministry of Health, Labor and Welfare (MHLW). Arzerra (ofatumumab) is submitted for the approval ...
Tags: new drug application, Arzerra, chronic lymphocytic leukemia
Genmab has announced that GlaxoSmithKline (GSK) entered into a patent settlement agreement with Genentech and City of Hope for Ofatumumab. GSK is Genmab's development and commercial collaborator for the CD20 antibody of atumumab. ...